Morrow John Kenneth, Lin Hui-Kuan, Sun Shao-Cong, Zhang Shuxing
Integrated Molecular Discovery Laboratory, Department of Experimental Therapeutics, MD Anderson Cancer Center, Houston, TX 77030, USA.
The University of Texas Graduate School of Biomedical Sciences, Houston, TX 77030, USA.
Future Med Chem. 2015;7(17):2333-50. doi: 10.4155/fmc.15.148. Epub 2015 Dec 2.
Ubiquitination, the structured degradation and turnover of cellular proteins, is regulated by the ubiquitin-proteasome system (UPS). Most proteins that are critical for cellular regulations and functions are targets of the process. Ubiquitination is comprised of a sequence of three enzymatic steps, and aberrations in the pathway can lead to tumor development and progression as observed in many cancer types. Recent evidence indicates that targeting the UPS is effective for certain cancer treatment, but many more potential targets might have been previously overlooked. In this review, we will discuss the current state of small molecules that target various elements of ubiquitination. Special attention will be given to novel inhibitors of E3 ubiquitin ligases, especially those in the SCF family.
泛素化是细胞蛋白质的有序降解和周转过程,受泛素-蛋白酶体系统(UPS)调控。大多数对细胞调节和功能至关重要的蛋白质都是该过程的作用靶点。泛素化由三个酶促步骤组成,该途径中的异常可导致肿瘤发生和进展,这在许多癌症类型中都有观察到。最近的证据表明,针对UPS进行靶向治疗对某些癌症治疗有效,但可能还有更多潜在靶点此前被忽视了。在本综述中,我们将讨论靶向泛素化各个环节的小分子的研究现状。我们将特别关注E3泛素连接酶的新型抑制剂,尤其是SCF家族中的抑制剂。